Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04283669 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04283669 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 12 participants.
The verdict
NCT04283669, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.
Interventions
- DRUG Crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2025-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04283669
The ClinicalTrials.gov registry entry for NCT04283669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crizotinib is the first listed.
NCT04283669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04283669 about?
NCT04283669 is a clinical study titled "Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas". Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 c...
What is the current status of trial NCT04283669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-02-18. Estimated completion is 2025-02-25.
What interventions are being tested in trial NCT04283669?
The interventions under investigation include: Crizotinib (DRUG).
Who is sponsoring clinical trial NCT04283669?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.